| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 02/18/2003 | US6521629 2-amine substituted quinoline or quinozoline derivatives useful for treating benign prostatic hyperplasia |
| 02/18/2003 | US6521626 Inhibiting binding of alpha 4 integrins to their ligands; prophylaxis and treatment of immune or inflammatory disorders |
| 02/18/2003 | US6521624 Synthesis and use of retinoid compounds having negative hormone and/or antagonist activities |
| 02/18/2003 | US6521622 Fungicidal heterocyclic aromatic amides and their compositions, methods of use and preparation |
| 02/18/2003 | US6521621 1-(1,2-disubstituted piperidinyl)-4-substituted piperazine derivatives |
| 02/18/2003 | US6521620 Suppressing tumors, especially breast cancers; antiproli-ferative agents; arthritis, vascular restenosis, psoriasis and angiogenesis; extremely low cytotoxicity |
| 02/18/2003 | US6521617 Treatment of apoptotic cell death |
| 02/18/2003 | US6521616 Administering taurolidine, taurultam, or a biologically active derivative; induces tumor cell death by apoptosis. |
| 02/18/2003 | US6521615 Administering calcium antagonist and reducing calcium pyrophosphate crystal deposition in an animal with pyrophosphate gout or osteoarthritis; diltiazem, nifedipine |
| 02/18/2003 | US6521612 Antibiotic compounds |
| 02/18/2003 | US6521610 4-Haloalkyl-3-heterocyclylpyridines and 4-haloalkyl-5-heterocyclyl-pyrimidines, processes for their preparation, compositions comprising them, and their use as pesticides |
| 02/18/2003 | US6521609 Using such as amino acid derivatives or serotonin receptor agonists; side effect reduction |
| 02/18/2003 | US6521608 Pulsed administration that avoids development of severe symptomatic or life threatening hypercalcemia |
| 02/18/2003 | US6521606 Matrix metalloproteinase inhibitors |
| 02/18/2003 | US6521603 Fungicides for the control of take-all disease of plants |
| 02/18/2003 | US6521600 Antimicrobial activity against pathogenic microorganisms; culturing and isolating |
| 02/18/2003 | US6521598 Peptide consisting of an amino acid sequence 1: SPSVDKARAEL; induces transplant tolerance |
| 02/18/2003 | US6521422 Fhm, a novel member of the TNF ligand supergene family |
| 02/18/2003 | US6521417 Incubating permeabilized cells expressing mutant kinase with radiolabeled analog; cytolysis, separation by sodium dodecyl sulfate polyacrylamide gel electrophoresis |
| 02/18/2003 | US6521412 Drug screening for anticarcinogenic agents and agents to treat atherosclerosis and neurodegenerative disorders |
| 02/18/2003 | US6521407 Methods for determining chemosensitivity of cancer cells based upon expression of negative and positive signal transduction factors |
| 02/18/2003 | US6521271 Administering a turmeric component and glycolic acid; tumerin or curcumin |
| 02/18/2003 | US6521270 Compositions comprising nitrofurantoin and uva ursi |
| 02/18/2003 | US6521269 Compositions and methods for enhancing therapeutic effects |
| 02/18/2003 | US6521268 Antibacterial and anti-inflammatory compositions with Inula helenium L. extract and water soluble chitosan |
| 02/18/2003 | US6521266 Choline bitartrate, dimethylaminoethanol, Vitamin E succinate, Gingko biloba, St. John's Wort, Huperzine A, 5-Hydroxytryptophan, Cysteamine HCL, increases cholinergic tone and growth hormone synthesis and inhibits somatostatin |
| 02/18/2003 | US6521265 Mixing anhydrous ferrate (VI) salt which hydrates to produce Fe+3 with blood flowing from a wound or water to form a paste; applying paste to the wound; K2FeO4 becomes FeOOH in water, which upon drying, yields ultrafine Fe2O3 |
| 02/18/2003 | US6521262 Solid instant-release forms of administration and process for producing the same |
| 02/18/2003 | US6521259 Controlled release material comprising polyanhydrides, copolymers of lactic acid and glycolic acid, polylactic acid, polyglycolic acid, polyesters, polyorthoesters, proteins, polysaccharides; ouabain, digoxin |
| 02/18/2003 | US6521256 Stabilized pharmaceutical composition |
| 02/18/2003 | US6521255 For treatment of gastrointestinal disorders; drug delivery |
| 02/18/2003 | US6521254 Single-dose antihistamine/decongestant formulations for treating rhinitis |
| 02/18/2003 | US6521253 Low molecular weight peptide thrombin inhibitor having pH dependent solubility and a combination of microcrystalline cellulose and sodium starch glycollate |
| 02/18/2003 | US6521252 Comprises one or several disulphide bonds; cationic lipid type |
| 02/18/2003 | US6521250 Transdermal therapeutic system containing estradiol |
| 02/18/2003 | US6521242 Method for sequestration of nasal secretion skin irritants with facial tissue |
| 02/18/2003 | US6521241 That can bind a cytokine; clay, silica, titanium dioxide, and combinations thereof |
| 02/18/2003 | US6521240 That can bind a cytokine; clay, silica, titanium dioxide, and combinations thereof |
| 02/18/2003 | US6521226 Administering Paraoxonase-1 (PON-1), an expressed protein that has hydrolase activity for organophosphates, and antioxidation activity for low-density lipoprotein (LDL) |
| 02/18/2003 | US6521225 AAV vectors |
| 02/18/2003 | US6521222 Topical cosmetics such as strontium 2,4-pentanedionate applied to keratin fibers, nails and/or mucous membranes for injuries, eczema, ulcers, fibrosis, psoriasis, pruritus, dermatitis, warts and for aging or wrinkle resistance |
| 02/18/2003 | US6521213 Administering mixtures of lipids, surfactants, dispersants, propellants and drugs such as antibiotics, bactericides, viricides and fungicides to the ears; protective coatings that reduce surface tension of the air/liquid interfaces |
| 02/18/2003 | US6521212 Method for treating peripheral vascular disease by administering benzindene prostaglandins by inhalation |
| 02/18/2003 | CA2419838A1 Heart muscular cell apoptosis inhibitors and remedies/preventives for heart diseases |
| 02/18/2003 | CA2351004C Formulation |
| 02/18/2003 | CA2264508C Substituted benzocycloheptapyridine derivatives useful for inhibition of farnesyl protein transferase |
| 02/18/2003 | CA2218750C Topical treatment and/or prevention of sagging subcutaneous muscle and overlying cutaneous tissue using acetylcholine precursors and catecholamines |
| 02/18/2003 | CA2112237C Cosmetic compositions containing oligosaccharides |
| 02/18/2003 | CA2085750C Osteoinductive pharmaceutical formulations |
| 02/18/2003 | CA2079289C Cardioprotective tocopherol analogs |
| 02/18/2003 | CA2073042C Phenylethanolamines, drugs containing these compounds, and a method of preparing them |
| 02/18/2003 | CA2051520E Use of folic acid and its derivatives for reducing the toxicity of gar-transformylase inhibitors |
| 02/16/2003 | CA2397698A1 Difluoromethylene aromatic ethers as inhibitors of glycine transport |
| 02/15/2003 | CA2397371A1 Pharmaceutical combinations for the treatment of neurodegenerative diseases |
| 02/15/2003 | CA2392305A1 Adrenic acid receptor and uses thereof |
| 02/14/2003 | WO2002018326A1 Novel propenohydroxamic acid derivatives |
| 02/14/2003 | CA2423733A1 Novel propenohydroxamic acid derivatives |
| 02/13/2003 | WO2003012441A1 Method for detecting modulators of notch signalling |
| 02/13/2003 | WO2003012432A1 Erythropoietin and anti-tumor necrosis factor alpha combination therapy |
| 02/13/2003 | WO2003012112A1 Methylation resistant vectors |
| 02/13/2003 | WO2003012105A2 Vegf isoform |
| 02/13/2003 | WO2003012093A2 Regulator of calcineurin |
| 02/13/2003 | WO2003012072A2 Monoclonal antibodies to activated erbb family members and methods of use thereof |
| 02/13/2003 | WO2003012051A2 Inhibitor of dna methylation |
| 02/13/2003 | WO2003012043A2 Enhancing organ maturity in neonates and predicting their duration of intensive care |
| 02/13/2003 | WO2003011905A1 Novel serine protease |
| 02/13/2003 | WO2003011898A2 Synthetic or natural peptides binding protein phosphatase 2a, identification method and uses |
| 02/13/2003 | WO2003011893A2 Immunologically significant herpes simplex virus antigens and methods for using same |
| 02/13/2003 | WO2003011887A2 Antisense modulation of apolipoprotein b expression |
| 02/13/2003 | WO2003011884A1 Process for the preparation of ribavirin |
| 02/13/2003 | WO2003011883A2 Process for the preparation of l-ribavirin |
| 02/13/2003 | WO2003011881A2 Sugar derivatives of hydromorphone, dihydromorphine and dihydroisomorphine, compositions thereof and uses for treating or preventing pain |
| 02/13/2003 | WO2003011880A1 Glucopyrano syloxybenzyl benzene derivative, medicinal composition containing the same, medicinal use thereof, and intermediate for production thereof |
| 02/13/2003 | WO2003011874A1 Compounds for use as surfactants |
| 02/13/2003 | WO2003011872A1 Platelet adp receptor inhibitors |
| 02/13/2003 | WO2003011870A1 Gonadotropin-releasing hormone receptor antagonists |
| 02/13/2003 | WO2003011868A1 Thienopyrimidinediones and their use in the modulation of autoimmune disease |
| 02/13/2003 | WO2003011866A1 Porphyrin-metal complexes and oxygen infusions containing the same |
| 02/13/2003 | WO2003011864A1 DERIVATIVES OF TRIAZOLYL-IMIDAZOPYRIDINE AND OF THE TRIAZOLYLPURINES USEFUL AS LIGANDS OF THE ADENOSINE A2a RECEPTOR AND THEIR USE AS MEDICAMENTS |
| 02/13/2003 | WO2003011863A1 Novel crystal forms of 9-substituted hypoxanthine derivatives |
| 02/13/2003 | WO2003011862A1 Non-nucleoside reverse transcriptase inhibitors |
| 02/13/2003 | WO2003011860A2 2-(3,5-BIS-TRIFLUOROMETHYL-PHENYL)-N-[6-(1,1-DIOXO-1λ6-THIOMORPHOLIN-4-YL)-4-(2-METHYL OR 4-FLUORO-2-METHYL SUBSTITUTED)PHENYL-PYRIDIN-3-YL]-N-METHYL-ISOBUTYRAMIDE |
| 02/13/2003 | WO2003011858A1 Substituted isoindoles and e use thereof |
| 02/13/2003 | WO2003011855A2 Pyrazole-derived kinase inhibitors and uses thereof |
| 02/13/2003 | WO2003011854A1 Pyrazole-derived kinase inhibitors and uses thereof |
| 02/13/2003 | WO2003011851A2 Aromatic hydroxamic acid derivatives useful as hdac inhibitors |
| 02/13/2003 | WO2003011846A2 Process for the preparation of 5-substituted isobenzofurans |
| 02/13/2003 | WO2003011843A1 Novel 2,4-diaminothiazole derivatives |
| 02/13/2003 | WO2003011842A1 Indane acetic acid derivatives and their use as pharmaceutical agents, intermediates, and method of preparation |
| 02/13/2003 | WO2003011841A1 1,2,4-triazin-3,5-diones as gonadotropin-releasing hormone receptor (gnrh) antagonists |
| 02/13/2003 | WO2003011839A1 1,3,5-triazine-2,4,6-triones, preparation and use as gonadotropin-releasing hormone receptor antagonists |
| 02/13/2003 | WO2003011834A1 Novel vinyl n-(2-benzoylphenyl)-l-tyrosine derivatives and their use as antidiabetics etc |
| 02/13/2003 | WO2003011833A1 Indazole or indole derivatives, their use in human medicine and more particularly in cancerology |
| 02/13/2003 | WO2003011832A1 Quinoline derivatives and use thereof as antitumor agents |
| 02/13/2003 | WO2003011831A1 Heteroarylheteroalkylamine derivatives and their use as inhibitors of nitric oxide synthase |
| 02/13/2003 | WO2003011830A1 Heteroarylheteroalkylamine derivatives and their use as inhibitors of nitric oxide synthase |
| 02/13/2003 | WO2003011826A1 Crystalline forms vi and vii of atorvastatin calcium |
| 02/13/2003 | WO2003011819A1 Butyric acid derivatives |
| 02/13/2003 | WO2003011814A1 Novel vinyl n-(2-benzoylphenyl)-l-tyrosine derivatives and their use as antidiabetics etc |
| 02/13/2003 | WO2003011812A1 NOVEL AMINE DERIVATIVE HAVING HUMAN β-TRYPTASE INHIBITORY ACTIVITY AND DRUGS CONTAINING THE SAME |